Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Harvard Business School
McKinsey
Mallinckrodt
Baxter

Last Updated: June 29, 2022

VYNDAMAX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Vyndamax patents expire, and when can generic versions of Vyndamax launch?

Vyndamax is a drug marketed by Foldrx Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-three patent family members in twenty-eight countries.

The generic ingredient in VYNDAMAX is tafamidis. One supplier is listed for this compound. Additional details are available on the tafamidis profile page.

DrugPatentWatch® Generic Entry Outlook for Vyndamax

Vyndamax will be eligible for patent challenges on May 3, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 31, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for VYNDAMAX
Drug Prices for VYNDAMAX

See drug prices for VYNDAMAX

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VYNDAMAX
Generic Entry Date for VYNDAMAX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VYNDAMAX

VYNDAMAX is protected by three US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VYNDAMAX is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VYNDAMAX

Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)

Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)

FDA Regulatory Exclusivity protecting VYNDAMAX

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY AND CARDIOVASCULAR-RELATED HOSPITALIZATION
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Foldrx Pharms VYNDAMAX tafamidis CAPSULE;ORAL 212161-001 May 3, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Foldrx Pharms VYNDAMAX tafamidis CAPSULE;ORAL 212161-001 May 3, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Foldrx Pharms VYNDAMAX tafamidis CAPSULE;ORAL 212161-001 May 3, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Foldrx Pharms VYNDAMAX tafamidis CAPSULE;ORAL 212161-001 May 3, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Foldrx Pharms VYNDAMAX tafamidis CAPSULE;ORAL 212161-001 May 3, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for VYNDAMAX

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pfizer Europe MA EEIG Vyndaqel tafamidis EMEA/H/C/002294
Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.
Authorised no no yes 2011-11-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for VYNDAMAX

When does loss-of-exclusivity occur for VYNDAMAX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1778
Estimated Expiration: See Plans and Pricing

Australia

Patent: 15313875
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2017003421
Estimated Expiration: See Plans and Pricing

Canada

Patent: 03194
Estimated Expiration: See Plans and Pricing

China

Patent: 6715405
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0211834
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 91461
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 56583
Estimated Expiration: See Plans and Pricing

Israel

Patent: 1037
Estimated Expiration: See Plans and Pricing

Japan

Patent: 16065042
Estimated Expiration: See Plans and Pricing

Patent: 20055832
Estimated Expiration: See Plans and Pricing

Patent: 22024014
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 91461
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 17002954
Estimated Expiration: See Plans and Pricing

Poland

Patent: 91461
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 91461
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 92252
Estimated Expiration: See Plans and Pricing

Patent: 17107235
Estimated Expiration: See Plans and Pricing

Serbia

Patent: 634
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 201700958Y
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 91461
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 2004059
Estimated Expiration: See Plans and Pricing

Patent: 170040314
Estimated Expiration: See Plans and Pricing

Spain

Patent: 01785
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 44902
Estimated Expiration: See Plans and Pricing

Patent: 1613880
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VYNDAMAX around the world.

Country Patent Number Title Estimated Expiration
Argentina 101778 FORMAS SÓLIDAS CRISTALINAS DE 6-CARBOXI-2-(3,5-DICLOROFENIL)-BENZOXAZOL See Plans and Pricing
Israel 251037 See Plans and Pricing
Japan 2022024014 6-カルボキシ-2-(3,5-ジクロロフェニル)-ベンゾオキサゾールの結晶性固体形態 (CRYSTALLINE SOLID FORMS OF 6-CARBOXY-2-(3,5-DICHLOROPHENYL)-BENZOXAZOLE) See Plans and Pricing
China 1747965 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding See Plans and Pricing
European Patent Office 3191461 FORMES CRISTALLINES SOLIDES DU 6-CARBOXY-2-(3,5-DICHLOROPHÉNYL)-BENZOXAZOLE (CRYSTALLINE SOLID FORMS OF 6-CARBOXY-2-(3,5-DICHLOROPHENYL)-BENZOXAZOLE) See Plans and Pricing
China 106715405 6‑羧基‑2‑(3,5‑二氯苯基)苯并噁唑的结晶固体形式 (Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole) See Plans and Pricing
Cyprus 1108467 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VYNDAMAX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1587821 C 2012 004 Romania See Plans and Pricing PRODUCT NAME: TAFAMIDISMEGLUMINA; NATIONAL AUTHORISATION NUMBER: EU/1/11/717/001; DATE OF NATIONAL AUTHORISATION: 20111116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/717/001; DATE OF FIRST AUTHORISATION IN EEA: 20111116
1587821 SPC/GB12/009 United Kingdom See Plans and Pricing PRODUCT NAME: TAFAMIDIS, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE MEGLUMINE SALT; REGISTERED: UK EU/1/11/717/001 20111118
1587821 91935 Luxembourg See Plans and Pricing 91935, EXPIRES: 20261116
1587821 126 5003-2012 Slovakia See Plans and Pricing PRODUCT NAME: TAFAMIDIS MEGLUMIN; REGISTRATION NO/DATE: EU/1/11/717/001 20111116
1587821 C20120001 00050 Estonia See Plans and Pricing PRODUCT NAME: VYNDAQEL - TAFAMIDIS;REG NO/DATE: C(2011)8519 FINAL 16.11.2011
1587821 6/2012 Austria See Plans and Pricing PRODUCT NAME: TAFAMIDIS; REGISTRATION NO/DATE: EU/1/11/717/001 20111116
1587821 1290005-6 Sweden See Plans and Pricing PERIOD OF VALIDITY AFTER CORRECTION (FROM - UNTIL): 20231220 - 20261117
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Merck
Colorcon
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.